Post Thrombotic Syndrome
26
2
3
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.5%
3 terminated out of 26 trials
72.7%
-13.8% vs benchmark
19%
5 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (26)
Incidence and Characteristic of CRT Persistent After Catheter Extraction in ICU Patients
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease
Exercise Tolerance After Venous Recanalization for Post-thrombotic Syndrome
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Compression Hosiery to Avoid Post-Thrombotic Syndrome
Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol
Angioplasty-stenting vs Optimal Medical Treatment on Post-thrombotic Syndrome Reduction
Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PE
Long-Term Post Thrombotic Syndrome Assessment (CELEST Long Term).
Structured Exercise Versus Endovascular Reconstruction in Post Thrombotic Syndrome
Long Term Assessment of Post Thrombotic Syndrome : OPTIMEV Study ( SPOT )
Non-elastic Compression Garment Therapy Versus Control for Deep Vein Thrombosis
EXERT: Exercise Physiology After Thrombosis
Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis
Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT)
Treatment Trial for Post-Thrombotic Syndrome
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE